Universal Ibogaine advises further on application for Management Cease Trade Order

Core Viewpoint - Universal Ibogaine Inc. is seeking a Management Cease Trade Order (MCTO) from the Alberta Securities Commission due to delays in filing required financial documents, which is attributed to limited financial resources and ongoing restructuring efforts [1][3][4] Group 1: MCTO Application - The company has applied for a temporary MCTO under National Policy 12-203, which would restrict trading of its securities by the CEO and the currently vacant CFO until the MCTO is revoked or the required filings are completed [1][2] - There is no guarantee that the MCTO will be granted, but the general public can still trade the company's common shares during this period [2] Group 2: Required Filings - The company failed to file its audited consolidated financial statements for the year ended July 31, 2025, along with the related management's discussion and analysis and CEO and CFO certificates by the November 28, 2025 deadline [3] - The delay is due to limited financial resources affecting the completion of the audit, and the company aims to rectify this situation and complete the required filings by January 30, 2026 [4] Group 3: Compliance and Reporting - Until the required filings are completed, the company will adhere to alternative information guidelines set out in NP 12-203, which includes issuing bi-weekly default status reports via news releases [5] Group 4: Company Overview - Universal Ibogaine Inc. is focused on transforming addiction treatment using medicalized ibogaine, with plans for a Canadian clinical trial targeting opioid use disorder and future global licensing agreements [7]